Everpar Advisors LLC Buys 499 Shares of Eli Lilly and Company $LLY

Everpar Advisors LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 22.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,740 shares of the company’s stock after buying an additional 499 shares during the period. Eli Lilly and Company accounts for about 0.8% of Everpar Advisors LLC’s investment portfolio, making the stock its 23rd biggest holding. Everpar Advisors LLC’s holdings in Eli Lilly and Company were worth $2,091,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in LLY. Total Wealth Planning LLC raised its stake in Eli Lilly and Company by 3.0% in the 3rd quarter. Total Wealth Planning LLC now owns 31,948 shares of the company’s stock worth $24,377,000 after acquiring an additional 945 shares during the last quarter. Tealwood Asset Management Inc. boosted its position in Eli Lilly and Company by 40.5% during the third quarter. Tealwood Asset Management Inc. now owns 2,513 shares of the company’s stock worth $1,917,000 after purchasing an additional 725 shares in the last quarter. Fire Capital Management LLC grew its stake in Eli Lilly and Company by 7.5% in the 3rd quarter. Fire Capital Management LLC now owns 1,627 shares of the company’s stock valued at $1,241,000 after acquiring an additional 114 shares during the period. Valley National Advisers Inc. grew its position in shares of Eli Lilly and Company by 1.0% in the third quarter. Valley National Advisers Inc. now owns 4,884 shares of the company’s stock valued at $3,726,000 after purchasing an additional 49 shares during the period. Finally, J. L. Bainbridge & Co. Inc. increased its stake in Eli Lilly and Company by 11,690.5% during the 3rd quarter. J. L. Bainbridge & Co. Inc. now owns 61,782 shares of the company’s stock worth $47,139,000 after buying an additional 61,258 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,078.72 on Tuesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a market capitalization of $1.02 trillion, a P/E ratio of 52.78, a PEG ratio of 1.09 and a beta of 0.37. The company’s fifty day moving average is $992.14 and its two-hundred day moving average is $843.49.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 33.86%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on LLY shares. BMO Capital Markets set a $1,200.00 target price on shares of Eli Lilly and Company in a research report on Thursday, December 4th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.